Clinical trials
Completed Observational Seizures trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
105 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 105 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 16 |
| Eisai Co., Ltd. | 3 |
| UCB Pharma | 3 |
| AstraZeneca | 2 |
| Balikesir University | 2 |
| Brain Sentinel | 2 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| Eisai Limited | 2 |
| Eysz, Inc. | 2 |
| Hospices Civils de Lyon | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seizures | 105 |
| Epilepsy | 56 |
| Epilepsies, Partial | 6 |
| Epilepsy, Absence | 5 |
| Status Epilepticus | 5 |
| Arrhythmias, Cardiac | 3 |
| Encephalitis | 3 |
| Inflammation | 3 |
| Intracranial Hypertension | 3 |
| Spasms, Infantile | 3 |
Trials
Showing 1 to 25 of 105. Each trial links to its page on Pharma Observatory.
5 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.